|2.95||-0.0100||-0.34%||Vol 67.96K||1Y Perf -26.37%|
|Nov 29th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||15.00||Analyst Rating||Strong Buy 1.00|
|Potential %||408.48||Finscreener Ranking||★★ 45.66|
|Insiders Trans % 3/6/12 mo.||33/33/33||Value Ranking||+ 37.49|
|Insiders Value % 3/6/12 mo.||-79/-79/-79||Growth Ranking||★+ 41.15|
|Insiders Shares Cnt. % 3/6/12 mo.||-75/-75/-75||Income Ranking||— -|
|Price Range Ratio 52W %||4.87||Earnings Rating||Strong Buy|
|Market Cap||90.84M||Earnings Date||14th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|12/2024 FY||-0.91||-1 616.67||Negative|
|Next Report Date||-|
|Estimated EPS Next Report||-0.27|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||86.75K|
|Avg. Monthly Volume||161.91K|
|Avg. Quarterly Volume||249.04K|
Capricor Therapeutics Inc. (NASDAQ: CAPR) stock closed at 2.95 per share at the end of the most recent trading day (a -0.34% change compared to the prior day closing price) with a volume of 67.96K shares and market capitalization of 90.84M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 16 people. Capricor Therapeutics Inc. CEO is Linda Marban.
The one-year performance of Capricor Therapeutics Inc. stock is -26.37%, while year-to-date (YTD) performance is -23.58%. CAPR stock has a five-year performance of -61.69%. Its 52-week range is between 2.68 and 8.2212, which gives CAPR stock a 52-week price range ratio of 4.87%
Capricor Therapeutics Inc. currently has a PE ratio of -3.50, a price-to-book (PB) ratio of 6.53, a price-to-sale (PS) ratio of 59.95, a price to cashflow ratio of 15.70, a PEG ratio of -, a ROA of -60.79%, a ROC of -95.24% and a ROE of -118.11%. The company’s profit margin is -%, its EBITDA margin is -1 733.50%, and its revenue ttm is $1.59 Million , which makes it $0.06 revenue per share.
Of the last four earnings reports from Capricor Therapeutics Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.27 for the next earnings report. Capricor Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Capricor Therapeutics Inc. is Strong Buy (1), with a target price of $15, which is +408.48% compared to the current price. The earnings rating for Capricor Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Capricor Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Capricor Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.33, ATR14 : 0.16, CCI20 : 32.06, Chaikin Money Flow : 0.12, MACD : -0.09, Money Flow Index : 19.76, ROC : 3.86, RSI : 44.52, STOCH (14,3) : 39.44, STOCH RSI : 0.47, UO : 47.87, Williams %R : -60.56), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Capricor Therapeutics Inc. in the last 12-months were: Collier Earl (Buy at a value of $28 300), Collier Earl (Option Excercise at a value of $1 947), Dunbar George (Option Excercise at a value of $1 947), Earl M. Collier (Option Excercise at a value of $1 947), Frank Litvack (Option Excercise at a value of $19 498), George W. Dunbar (Option Excercise at a value of $1 947), Linda Marban (Option Excercise at a value of $28 841), Litvack Frank (Option Excercise at a value of $19 498), Louis V. Manzo (Option Excercise at a value of $1 947), Manzo Louis (Option Excercise at a value of $1 947), Musket David (Buy at a value of $22 712), Paul Gisbert Auwaerter (Buy at a value of $14 200), Xavier Avat (Option Excercise at a value of $293 377)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.